title: The I1307K APC polymorphism: prevalence in non-Ashkenazi Jews and evidence for a founder effect.
abstract: A missense mutation within the APC gene, I1307K, was described in Ashkenazi individuals at risk for colorectal cancer (CRC) and in the general population. The anecdotal reporting of the occurrence of this mutation in some non-Ashkenazi individuals led us to hypothesize that within the Jewish people, the I1307K polymorphism may reflect a founder mutation, and that the mutation is not restricted to ethnic Ashkenazis. To test that notion, and to establish the occurrence rate of the I1307K polymorphism in non-Ashkenazi Jewish populations, we screened Iraqi and Moroccan Jews and consecutive Jewish CRC patients and performed haplotype analysis with APC-linked markers in two I1307K carrier families. We analyzed Jewish individuals: 210 Moroccans, 160 Iraqis, 148 Ashkenazi, and 349 CRC patients (227 Ashkenazi and 122 non-Ashkenazi). The mutation detection scheme included PCR followed by denaturing gradient gel electrophoresis (DGGE) or modified restriction analysis (MRA). Haplotypes were assessed using three intragenic and three flanking markers. The I1307K polymorphism was detected in 29/227 Ashkenazi (12.8%), 2/122 (1.6%) non-Ashkenazi CRC patients, and in 2 individuals each (approximately 1%) within the Moroccan and Iraqi populations. Allelic pattern analysis in all our I1307K carriers, revealed a common haplotype for the three intragenic markers tested, in all mutation carriers, regardless of ethnic origin. The I1307K polymorphism, therefore, exists in all ethnic Jewish populations: Ashkenazi and non-Ashkenazi, with or without colon cancer. Jewish I1307K mutation carriers share a common allelic pattern with APC-linked markers. This strongly supports the notion of a founder mutation for I1307K.
authors.affiliation: Department of Gastroenterology, Chaim Sheba Medical Center, Tel-Hashomer, Israel. kiffa@post.tau.ac.il
authors.forename: R
authors.initials: R
authors.lastname: Shtoyerman-Chen
authors.forename: E
authors.initials: E
authors.lastname: Friedman
authors.forename: A
authors.initials: A
authors.lastname: Figer
authors.forename: M
authors.initials: M
authors.lastname: Carmel
authors.forename: Y
authors.initials: Y
authors.lastname: Patael
authors.forename: P
authors.initials: P
authors.lastname: Rath
authors.forename: H H
authors.initials: HH
authors.lastname: Fidder
authors.forename: S
authors.initials: S
authors.lastname: Bar-Meir
authors.forename: L
authors.initials: L
authors.lastname: Theodor
mesh_terms: D000230:Adenocarcinoma / Q000208:ethnology / Q000235:genetics; D011125:Adenomatous Polyposis Coli / Q000208:ethnology / Q000235:genetics*; D019943:Amino Acid Substitution; D015179:Colorectal Neoplasms / Q000208:ethnology / Q000235:genetics; D005061:Europe, Eastern / Q000208:ethnology; D005260:Female; D018703:Founder Effect; D005787:Gene Frequency; D017491:Genes, APC; D020022:Genetic Predisposition to Disease; D006239:Haplotypes / Q000235:genetics; D006801:Humans; D007493:Iraq / Q000208:ethnology; D007557:Israel / Q000453:epidemiology; D007585:Jews / Q000145:classification / Q000235:genetics*; D008297:Male; D009018:Morocco / Q000208:ethnology; D020125:Mutation, Missense; D010375:Pedigree; D011110:Polymorphism, Genetic; D015995:Prevalence